Karen Hunke
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Lilly USA, LLC at 27.1% of the total. Reporting peaked in 2021 at $7,471 and has fallen 65.7% since, to $2,560 in 2025. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 492 payments — averaging $41.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$5K
- AbbVie$4K
- UCB, Inc.$4K
- Johnson & Johnson$2K
- Novartis$1K
- Sun Pharmaceutical Industries Inc.$742
- plus $3K from 21 others
What the payments were for
- Consulting fees$3,37317%
- Speaking & faculty fees$7,26336%
- Food & beverage$9,01845%
- Education$6003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 47 | $5,487 |
| AbbVie(2 entities) | 115 | $4,150 |
| UCB, Inc. | 62 | $3,592 |
| Johnson & Johnson | 31 | $1,635 |
| Novartis | 24 | $1,316 |
| Sun Pharmaceutical Industries Inc. | 30 | $742 |
| E.r. Squibb & Sons, L.L.C. | 31 | $628 |
| Amgen | 35 | $480 |
| Regeneron Healthcare Solutions, Inc. | 13 | $373 |
| Galderma Laboratories, L.p. | 25 | $333 |
| Sanofi | 16 | $281 |
| Incyte Corporation | 15 | $276 |
| Pfizer | 12 | $213 |
| Boehringer Ingelheim | 8 | $157 |
| Dermavant Sciences, Inc. | 5 | $130 |
| Arcutis Biotherapeutics, Inc. | 2 | $116 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $57 |
| LEO Pharma Inc. | 3 | $52 |
| Organon | 3 | $30 |
| VYNE Pharmaceuticals Inc. | 2 | $26 |
| Blueprint Medicines Corporation | 1 | $25 |
| Botanix SB Inc | 1 | $24 |
| Organogenesis Inc. | 1 | $20 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Dermira, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,253 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $289,007 |
| Humira(Cf) PenAdalimumab | 18 | $265,168 |
| Dupixent PenDupilumab | 44 | $170,923 |
| OtezlaApremilast | 26 | $56,966 |
| Betamethasone Dipropionate | 88 | $4,205 |
| Tacrolimus | 35 | $3,226 |
| Fluorouracil | 23 | $1,976 |
| Doxycycline Hyclate | 73 | $1,730 |
| Clindamycin Phosphate | 29 | $1,484 |
| Cimetidine | 19 | $1,212 |
| Metronidazole | 15 | $826 |
| Doxycycline Monohydrate | 21 | $567 |
| Ketoconazole | 37 | $488 |
| Minoxidil | 12 | $237 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $480 | $56,96626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Ames
- Aubrey MolgaardAmes$238K
- Stefanie GaticaAnkeny$354K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
- Jaclyn MeisSioux City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.